LCM
XERS icon

Laurion Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Laurion Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20,756
Closed -$32K – 619
2022
Q2 		$32K Buy
+20,756
New +$43.8K ﹤0.01% 444
2020
Q2 		– Sell
-25,000
Closed -$49K – 1219
2020
Q1 		$49K Buy
+25,000
New +$108K ﹤0.01% 699

Other funds holding XERS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Laurion Capital Management's XERS Position: Q3 2022 in Review

Laurion Capital Management sold out of Xeris Biopharma Holdings (XERS) in Q3 2022, closing a stake of 20,756 shares — an estimated $32K sold.

Laurion Capital Management first reported a position in XERS in Q1 2020 and held it in 2 quarters. The position peaked at $49K in Q1 2020. 101 funds tracked by Wall St. Rank hold XERS as of Q3 2022.

  • Laurion Capital Management reported no remaining Xeris Biopharma Holdings position as of Q3 2022 after selling out during the quarter.
  • Laurion Capital Management sold 20,756 Xeris Biopharma Holdings shares in Q3 2022, an estimated $32K.
  • Laurion Capital Management first reported a position in Xeris Biopharma Holdings in Q1 2020 and held it in 2 quarters.
  • Laurion Capital Management's Xeris Biopharma Holdings position peaked at $49K in Q1 2020.
  • 101 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2022.

Based on Laurion Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.